Track market-moving stories before they get noisy

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest”) (NYSE: EG) a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions, today announced that it has published its Global Loss Triangles for the year ended December 31, 2025. These documents are available on the Company's investor relations website, under Financials/Annual Disclosures. The link can be found here: https://investors.everestglobal.com/financials/annual-.

It has been about a month since the last earnings report for Everest Group (EG - Free Report) . Shares have added about 0.6% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Everest Group due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Everest Group, Ltd. before we dive into how investors and analysts have reacted as of late.

Everest Group Q2 Earnings Beat Estimates on Lower Expenses

Everest Group reported second-quarter 2026 operating earnings of $14.85 per share, which beat the Zacks Consensus Estimate by 1.8%. The bottom line declined 14.5% year over year. Strong underwriting income from its core businesses supported the earnings beat.

Operating revenues of $3.96 billion decreased 11.8% year over year and missed the consensus estimate by 3.1%.

EG's Q2 Operating Update

Gross written premiums declined 19.4% year over year to $3.77 billion. Our estimate was $3.8 billion. The decrease reflected the continued runoff of the Legacy business and targeted reductions in selected Reinsurance Treaty lines. Net premiums earned fell 12.6% to $3.49 billion, reflecting lower business volumes. Our estimate was $3.6 billion.

Total claims and expenses fell 10.8% year over year to $3.28 billion. Our estimate was $3.4 billion. Incurred losses and loss-adjustment expenses declined 12.2%, while commission, brokerage, taxes and fees decreased 7.5%. Other underwriting expenses fell 11.4%.

Everest's Core Underwriting Results

Core gross written premiums decreased 5.9% year over year to $3.68 billion. On a comparable basis, excluding foreign-exchange movements and catastrophe reinstatement premiums, the decline was 7.1%. Growth in specialty lines was offset by lower property premiums and targeted reductions in U.S. casualty business.

Core underwriting income totaled $317 million and declined 29.2% year over year. The combined ratio deteriorated 300 basis points to 90%, reflecting higher catastrophe losses and underwriting expenses. The attritional combined ratio, which excludes catastrophes and prior-year reserve development, increased 170 basis points to 87.3%.

EG's Reinsurance Treaty Performance

Reinsurance Treaty gross written premiums declined 7.8% year over year to $2.72 billion. Our estimate was $2.6 billion. On a comparable basis, premiums fell 9.1%, led by reductions in Casualty XOL, Casualty Pro-Rata and property excess-of-loss business. Growth in Property Pro-Rata partly offset the decline.

The segment generated underwriting income of $283 million, which declined 31.5% year over year. Our estimate was $271.21 million. Its combined ratio increased 360 basis points to 88.5%, while the attritional combined ratio rose 220 basis points to 85.4%. Excluding elevated non-catastrophe weather losses, the attritional combined ratio would have been 82.7%.

Everest's Specialty Business Trends

Global Wholesale & Specialty gross written premiums were nearly unchanged at $958 million. Our estimate was $911.3 million. On a comparable basis, premiums declined 1%. Lower Workers’ Compensation and Specialty Casualty premiums were largely offset by growth in Other Specialty, Professional Liability and Accident and Health.

The segment recorded underwriting income of $34 million, which declined 2.9% year over year. Our estimate was $41.3 million. The combined ratio remained unchanged at 95.2%, while the attritional combined ratio improved 110 basis points to 93.8%. The attritional loss ratio improved 390 basis points, benefiting from changes in portfolio mix and underwriting actions.

EG's Investment and Expense Picture

Net investment income declined 1.7% year over year to $523 million because of lower alternative investment returns. Our estimate was $561.5 million. The annualized return on invested assets was 4.5% compared with 4.8% in the prior-year quarter.

Total investments and cash totaled $44.86 billion as of June 30, 2026, up 1.3% year over year. The fixed-maturity portfolio’s book yield was 4.5%. New money yields continued to exceed the portfolio yield, supporting future investment income generation.

Everest's Financial Position and Capital Return

Everest reported net income of $559 million, or $14.22 per share, compared with $680 million, or $16.10 per share, a year earlier. Annualized net operating return on equity was 14.9%, which contracted 470 basis points year over year, while annualized total shareholder return was 16.8%, which expanded 200 basis points year over year.

The company repurchased $395 million of shares during the quarter and paid $78 million in dividends. Book value per share increased to $398.83, up 5% from 2025-end. Cash flow from operations was $291 million, which declined 73% from the year-ago quarter.

How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.

The consensus estimate has shifted -6.9% due to these changes.

VGM ScoresAt this time, Everest Group has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. However, the stock has a score of A on the value side, putting it in the top 20% for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Everest Group has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

-

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. announced that its Board of Directors declared a dividend of $2.00 per common share. This dividend will be payable on or before September 25, 2026 to all shareholders of record as of September 09, 2026.

About Everest

Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.

Everest common stock (NYSE: EG) is a component of the S&P 500 index.

Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.

More News From Everest Group, Ltd.

Back to Newsroom

A Quiet Outperformer With a Catastrophe CaveatEverest Group NYSE: EG reported second-quarter operating income of $585 million, supported by underwriting income and investment income, as management emphasized underwriting discipline, portfolio adjustments and capital returns amid competitive reinsurance market conditions.

Get Everest Group alerts:

President and CEO Jim Williamson said the company generated an annualized after-tax net operating return on equity of 14.9% and annualized total shareholder return of 16.8%. Book value per share excluding unrealized gains and losses increased 12% year over year, while operating earnings per share were $14.85, according to Executive Vice President and CFO Elias Habayeb.

REITs Set for a 2026 Rebound? 7 Top Picks as Rate Cuts ApproachThe company’s core businesses—Reinsurance Treaty and Global Wholesale & Specialty—produced $317 million of underwriting income on a 90% combined ratio. Gross written premiums in those businesses totaled $3.7 billion, down about 7% on a comparable basis from the prior-year quarter as Everest reduced or exited business that did not meet its return thresholds.

Reinsurance Treaty Results and Market Conditions Everest’s Reinsurance Treaty business generated $283 million in underwriting income and posted an 88.5% combined ratio. Gross written premiums declined approximately 9% year over year on a constant-currency basis, excluding reinstatement premiums. Casualty premiums fell 19%, while property premiums were relatively flat as growth in property pro rata business offset reductions in the catastrophe portfolio.

3 High-Momentum Gold Stocks Surging on the Metals RallyWilliamson said the company continued to reduce exposure to U.S. casualty lines while selectively cutting business where pricing or structure did not meet return requirements. He added that Everest is expanding selectively in specialty lines globally, including areas such as data centers, construction and renewable energy.

Property pricing declined by roughly 15% to 20% across the market at the June 1 and July 1 renewal periods, according to Williamson. Everest’s property catastrophe portfolio saw pricing decline by about 10% across those periods. He said terms and conditions have been largely maintained and attachment points have remained relatively stable.

During the question-and-answer session, Williamson said Everest moved its average attachment point slightly higher during midyear renewals and shifted capacity among programs based on risk-adjusted economics. He said the company did not move lower in reinsurance towers to obtain better pricing.

Habayeb said the Reinsurance Treaty segment’s attritional loss ratio rose 140 basis points to 57.1%, largely due to higher weather-related non-catastrophe losses. Excluding those losses, the ratio would have been 54.4%, representing a 130-basis-point year-over-year improvement driven by business mix and improved loss experience. He said investors should view the near-term attritional loss ratio for the treaty operation as being in the mid-50s.

Wholesale and Specialty Progress Global Wholesale & Specialty reported a 95.2% combined ratio, unchanged from the prior-year quarter. Its attritional loss ratio improved 390 basis points to 60.6%, which Habayeb attributed to underwriting actions and an improved mix of business.

Gross written premiums were roughly flat in the segment. Growth in niche specialty products and international markets was offset by intentional reductions in U.S. property and casualty business. Everest reported double-digit international growth across financial lines, marine, political violence and selected specialty property markets.

Rate across the segment was flat, as double-digit property rate declines were offset by rate increases in casualty. Catastrophe losses added 1.4 points to the combined ratio, while the prior-year quarter had minimal catastrophe losses. Habayeb said Everest continues to expect the segment to deliver combined ratios in the mid-to-high 90s in the near term.

Reserve Actions and Investment Income Everest reported no net prior-year reserve development in the quarter. Habayeb said favorable development in short-tail lines was offset by a higher industry loss estimate for the Baltimore Bridge collapse and strengthening in casualty reserves.

The company increased its reserve estimate for the Baltimore Bridge matter by about $55 million, bringing its estimate in line with an industry loss range of approximately $2.8 billion to $3 billion. Everest also strengthened North American casualty treaty reserves by just under $200 million. Habayeb said loss emergence was concentrated in older accident years, but the company reflected the experience across most accident years.

Management did not adjust 2026 casualty loss picks during the quarter. Habayeb said casualty loss trends have remained relatively stable since the prior reserve study, ranging from high single digits to low double digits depending on the line of business. Everest expects to complete annual reserve studies for most long-tail lines later in the third quarter and plans to publish enhanced global loss-triangle disclosures during the coming month.

Net investment income was $523 million, modestly below the prior-year period due to lower alternative investment returns. The investment portfolio’s book yield was 4.5%, compared with a current new-money yield closer to 5%, Habayeb said.

Third-Party Capital and Share Repurchases Everest said its Mt. Logan Capital Management platform had approximately $3.4 billion in assets under management as of July 1, up 89% from the beginning of 2025. The growth included the launch of Annapurna Re, a casualty and specialty reinsurance sidecar.

The company expects to cede roughly $200 million of premium per quarter to Annapurna Re over the next three years. Management said the sidecar should be modestly accretive to underwriting income and return on equity over time, while reducing net investment income. Williamson said the arrangement is structured as a quota share and is intended to align Everest’s experience with that of its third-party capital partners.

Capital returns remained a priority. Everest repurchased approximately 1.2 million shares during the second quarter for $395 million at an average price of $342 per share, alongside dividends, resulting in a quarterly payout ratio of 81%. Since Williamson became CEO in January 2025, the company has deployed $1.5 billion toward share repurchases and reduced shares outstanding by more than 10%.

Habayeb said Everest views $300 million of quarterly repurchases as a floor and expects to exceed that amount when appropriate. The company also has more than $1 billion of capital supporting its legacy business that is expected to be released over time as reserves run off. Everest’s commercial retail insurance transition to AIG remains on track, with roughly $250 million of net premiums left to be earned in the second half of 2026.

About Everest Group (NYSE:EG)Everest Group NYSE: EG is a global research and consulting firm specializing in strategic advisory, market intelligence, and data-driven analysis for business process, information technology, and emerging technology services. The company provides insights and benchmarks that help enterprises and service providers optimize digital transformation initiatives, sourcing strategies, and operational performance. Through its proprietary research frameworks and data analytics, Everest Group delivers actionable guidance on areas such as automation, cloud migration, customer experience, and supply chain resilience.

With offerings that span advisory engagements, managed services research, and consulting projects, Everest Group serves multiple industry verticals, including banking and financial services, healthcare, manufacturing, telecommunications, and retail.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Everest Group Right Now?Before you consider Everest Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Everest Group wasn't on the list.

While Everest Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Everest Group, Ltd. (EG) Q2 2026 Earnings Call Transcript

Everest Group (EG - Free Report) came out with quarterly earnings of $14.85 per share, beating the Zacks Consensus Estimate of $14.59 per share. This compares to earnings of $17.36 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +1.78%. A quarter ago, it was expected that this reinsurance company would post earnings of $14.03 per share when it actually produced earnings of $16.08, delivering a surprise of +14.61%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Everest Group, which belongs to the Zacks Insurance - Multi line industry, posted revenues of $3.96 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 3.07%. This compares to year-ago revenues of $4.49 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Everest Group shares have added about 17.5% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Everest Group?While Everest Group has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Everest Group was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $9.21 on $3.96 billion in revenues for the coming quarter and $52.86 on $15.89 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Insurance - Multi line is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Horace Mann (HMN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This provider of auto and homeowners' insurance for teachers and other educators is expected to post quarterly earnings of $0.67 per share in its upcoming report, which represents a year-over-year change of -36.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Horace Mann's revenues are expected to be $443.9 million, up 7.8% from the year-ago quarter.

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (NYSE: EG), a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions, today reported its second quarter 2026 results. “Everest delivered a strong quarter driven by meaningful contributions from both underwriting income across our Core businesses and investments resulting in an annualized total shareholder return of 16.8%. The results this quarter show the strength of the fran.

Posted by Defense World Staff on Jul 28th, 2026

Dimensional Fund Advisors LP lessened its stake in shares of Everest Group, Ltd. (NYSE:EG – Free Report) by 3.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 414,923 shares of the company’s stock after selling 14,469 shares during the quarter. Dimensional Fund Advisors LP owned 0.83% of Everest Group worth $135,609,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Bartlett & CO. Wealth Management LLC lifted its holdings in Everest Group by 2.1% during the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 1,682 shares of the company’s stock valued at $571,000 after purchasing an additional 34 shares during the last quarter. Siemens Fonds Invest GmbH grew its stake in Everest Group by 3.3% during the fourth quarter. Siemens Fonds Invest GmbH now owns 1,067 shares of the company’s stock worth $364,000 after buying an additional 34 shares during the last quarter. V Square Quantitative Management LLC grew its stake in Everest Group by 4.0% during the first quarter. V Square Quantitative Management LLC now owns 968 shares of the company’s stock worth $316,000 after buying an additional 37 shares during the last quarter. Brown Brothers Harriman & Co. increased its holdings in shares of Everest Group by 27.6% during the fourth quarter. Brown Brothers Harriman & Co. now owns 171 shares of the company’s stock worth $58,000 after buying an additional 37 shares in the last quarter. Finally, GenTrust LLC raised its stake in shares of Everest Group by 4.8% in the fourth quarter. GenTrust LLC now owns 874 shares of the company’s stock valued at $297,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 92.64% of the company’s stock.

Everest Group Stock Performance Everest Group stock opened at $389.65 on Tuesday. The company has a current ratio of 0.37, a quick ratio of 0.37 and a debt-to-equity ratio of 0.23. Everest Group, Ltd. has a 1 year low of $302.44 and a 1 year high of $390.53. The company has a market cap of $15.42 billion, a PE ratio of 7.92, a PEG ratio of 0.60 and a beta of 0.29. The company’s 50-day moving average is $353.34 and its two-hundred day moving average is $340.69.

Everest Group (NYSE:EG – Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported $16.08 EPS for the quarter. Everest Group had a net margin of 11.76% and a return on equity of 14.70%. The company had revenue of $4.07 billion during the quarter. Equities analysts anticipate that Everest Group, Ltd. will post 52.86 earnings per share for the current year.

Everest Group Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Friday, June 12th were paid a dividend of $2.00 per share. The ex-dividend date of this dividend was Friday, June 12th. This represents a $8.00 dividend on an annualized basis and a dividend yield of 2.1%. Everest Group’s payout ratio is 16.27%.

Insider Activity at Everest Group In related news, CEO Jason Keen sold 775 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $351.84, for a total value of $272,676.00. Following the completion of the sale, the chief executive officer owned 8,170 shares in the company, valued at approximately $2,874,532.80. This represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets EG has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on Everest Group from $355.00 to $360.00 and gave the stock an “equal weight” rating in a research report on Monday, July 6th. Mizuho increased their target price on Everest Group from $388.00 to $418.00 and gave the stock a “neutral” rating in a report on Thursday, July 9th. Wells Fargo & Company raised their target price on Everest Group from $356.00 to $373.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. BMO Capital Markets lifted their price target on Everest Group from $366.00 to $376.00 and gave the company a “market perform” rating in a report on Thursday, May 14th. Finally, UBS Group set a $355.00 price target on shares of Everest Group in a research report on Thursday, May 21st. Four equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $387.73.

Get Our Latest Analysis on Everest Group

Everest Group Profile (Free Report)

Everest Group (NYSE:EG) is a global research and consulting firm specializing in strategic advisory, market intelligence, and data-driven analysis for business process, information technology, and emerging technology services. The company provides insights and benchmarks that help enterprises and service providers optimize digital transformation initiatives, sourcing strategies, and operational performance. Through its proprietary research frameworks and data analytics, Everest Group delivers actionable guidance on areas such as automation, cloud migration, customer experience, and supply chain resilience.

With offerings that span advisory engagements, managed services research, and consulting projects, Everest Group serves multiple industry verticals, including banking and financial services, healthcare, manufacturing, telecommunications, and retail.

Featured Stories Five stocks we like better than Everest Group AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight

Receive News & Ratings for Everest Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everest Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Purchases 82,340 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

NEXT HEADLINE »Dimensional Fund Advisors LP Buys 175,679 Shares of Visteon Corporation $VC

PROVO, Utah--(BUSINESS WIRE)---- $GDOT #BaaS--Recognition underscores Green Dot's decades-long commitment to supporting the financial wellness of working Americans.

Wall Street expects a year-over-year decline in earnings on lower revenues when Everest Group (EG - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis reinsurance company is expected to post quarterly earnings of $14.59 per share in its upcoming report, which represents a year-over-year change of -16%.

Revenues are expected to be $4.09 billion, down 9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.14% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Everest Group?For Everest Group, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.67%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that Everest Group will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Everest Group would post earnings of $14.03 per share when it actually produced earnings of $16.08, delivering a surprise of +14.61%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Everest Group appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerAmong the stocks in the Zacks Insurance - Multi line industry, Slide Insurance Holdings, Inc. (SLDE - Free Report) , is soon expected to post earnings of $0.88 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +57.1%. This quarter's revenue is expected to be $370.8 million, up 41.7% from the year-ago quarter.

The consensus EPS estimate for Slide Insurance Holdings, Inc. has been revised 6.3% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of +7.43%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Slide Insurance Holdings, Inc. will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

NEW YORK--(BUSINESS WIRE)--Global digital services leader TP (formerly Teleperformance) today announced it has been named a Leader in Everest Group's Healthcare CXM Intelligent Operations PEAK Matrix® Assessment, reinforcing its position as a strategic partner for healthcare organizations navigating rising complexity, regulatory demands, and growing consumer expectations. Everest Group evaluated 24 providers in this year's assessment, with TP ranked among the top performers for delivering high-.

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (NYSE: CTEV), a technology, data, and insights company focused on making healthcare more affordable and transparent, today announced it has been recognized as a Leader in the Everest Group Pre-payment Integrity Solutions PEAK Matrix® Assessment 2026. The recognition and ascent into the Leader category reflects Claritev's longstanding history and continued investment in technology-enabled payment integrity that helps health plans identify potent.

Everest Group delivered outstanding Q1-2026 results, with net income of $653M ($16.21/share) and a 16.8% ROE, underscoring robust earnings power. EG trades at a compelling valuation, generating $60–$65 annualized EPS while priced at $320–$360, with tangible book value near $407/share and a conservative $420/share target by Jan 2027. Despite competitive pressures and softening property catastrophe pricing, EG maintains structural discipline, focusing on profitability and selective capacity deployment.

Key Takeaways EG's net investment income delivered a 27% CAGR from 2020 to 2025, reflecting sustained portfolio growth. NII rose 15.5% year over year in first-quarter 2026, driven by fixed income and alternative investments. Growing insurance float, higher reinvestment yields, and disciplined portfolio management support earnings. Everest Group, Ltd. (EG - Free Report) has become one of the major beneficiaries of the higher interest rate environment, with net investment income (NII) serving as an increasingly important contributor to earnings alongside its insurance and reinsurance underwriting operations.

NII has become an increasingly valuable component of Everest Group's earnings profile. The combination of a growing insurance float, disciplined investment management, and a higher-yield investment environment strengthens the company's ability to generate consistent profits, complementing its underwriting performance and supporting long-term shareholder value creation.

A significant portion of the investment portfolio consists of fixed income securities, and smaller portions consist of equity securities and other investments, such as limited partnerships and other alternative investments. The metric should continue to gain from an increase in limited partnership income, higher income from fixed maturity investments, an increase in income from other alternative investments, higher income from short-term investments, and cash.

The insurer’s investment income has shown continuous improvement. The metric has delivered a five-year (2020-2025) CAGR of 27%. 
NII increased 15.5% year over year for the three months ended March 31, 2026, largely driven by strong alternative asset returns, fixed income portfolio growth, and strong limited partnership returns.

EG's net investment income is primarily driven by the growth of its investment portfolio, higher reinvestment yields in a higher-rate environment, expanding insurance float, and disciplined portfolio management.

NII significantly boosts top-line growth and overall profitability for EG, complementing the company's underwriting operations. While insurance premiums are the primary source of revenue, NII provides a recurring stream of earnings generated from investing the company's insurance float and shareholders' capital.

What About Other Insurers?Chubb Limited's (CB - Free Report) net investment income is an important earnings contributor. The metric benefits from higher interest rates and stronger portfolio yields, providing a steady source of earnings beyond underwriting profits. This helps improve profitability, offset claim volatility and strengthen overall financial performance.

The Travelers Companies, Inc.’s (TRV - Free Report) net investment income is a material contributor to the company’s results of operations, consistently providing a reliable source of earnings that complements its underwriting activities. Net investment income acts as a second earnings engine for this property and casualty insurer after underwriting profit. Thus, even if underwriting profit weakens because of higher catastrophe losses, solid net investment income can help offset earnings pressure.

EG’s Price PerformanceShares of EG have gained 1.8% in the past year, outperforming the industry.

Image Source: Zacks Investment Research

EG’s UndervaluationThe stock is overvalued compared with its industry. It is currently trading at a price-to-book value multiple of 0.89, lower than the industry average of 2.78. It carries a Value Score of A.

Image Source: Zacks Investment Research

Estimate Movement for EGThe Zacks Consensus Estimate for EG’s second-quarter 2026 and third-quarter 2026 EPS has moved down 0.1% and 0.2%, respectively, in the past 30 days. The same for full-year 2026 EPS has moved up 0.9% in the past 30 days.

Image Source: Zacks Investment Research

-

Magnit achieved Leader status in Everest Group’s global, North America, and EMEA assessments and Star Performer status in EMEA

FOLSOM, Calif.--(BUSINESS WIRE)--Magnit Global™, the global leader in contingent workforce management solutions, today announced its designation as a Leader in the 2026 Vendor Management System (VMS) PEAK Matrix® Assessment released by Everest Group. Magnit achieved Leader distinction in all regions measured: global, North America, and EMEA. In addition, Magnit was recognized as a Star Performer in EMEA for its year-over-year regional growth and positive client feedback.

Everest Group’s PEAK Matrix® assessment analyzes the VMS landscape and performance of nearly 50 service providers. It offers comparative evaluations of providers, locations, and products and solutions within various market segments. It provides unbiased evaluation of factors such as vision, capabilities/functionality, talent availability, market success/impact, and cost.

The report divides VMS providers into three main categories: Leaders, Major Contenders, and Aspirants.

“Magnit Global advanced its platform capabilities through AI-led innovation, deeper ecosystem integrations, and expanded multi-channel orchestration to manage contingent programs at scale,” says Krishna Charan, Vice President at Everest Group. “Its investments in Maggi, spanning candidate, workflow, knowledge, and reporting agents, along with enhanced services procurement functionality, SourceMatch, and Pay Intelligence, reinforce its position as a Leader in Everest Group’s 2026 Global Vendor Management System (VMS) PEAK Matrix® Assessment.”

Magnit earned Leader distinction for its ability to provide end-to-end contingent workforce management through a robust global footprint that serves diverse industries. The assessment highlighted several of Magnit’s strengths including:

Embedded Generative AI: Key functionalities provided by Maggi, Magnit’s GenAI agent, improve decision-making, automate workflows, and deliver predictive workforce insights. SOW and Services Procurement: AI-assisted SOW creation and enhanced collaboration and flexibility ease the SOW process. Direct Sourcing: Supporting client-specific talent pools and Magnit’s talent redeployment marketplace enable better access to talent. Data and Analytics: Magnit VMS users gain better insights from real-time dashboards, predictive analytics, and supplier scorecards. “Magnit Global is proud to be recognized as a global and regional Leader for our Vendor Management System. This acknowledgement reflects our investment in providing AI-enabled, data-driven solutions that help our clients unlock smarter, faster, more cost-effective ways to manage their contingent workforce and drive business growth.”
– Chandra Dhandapani, Magnit Global CEO

Read more about Everest Group’s 2026 PEAK Matrix® Assessment of Magnit VMS here.

About Magnit Global

Magnit is a leading provider of contingent workforce management solutions, helping enterprises source, manage, and optimize their extended workforces at scale. Through its proprietary VMS, managed services, and supplier intelligence platforms, Magnit delivers the visibility, compliance, and cost control that modern workforce programs demand. For more information, visit magnitglobal.com.

About Everest Group’s PEAK Matrix® Reports

Licensed extracts taken from Everest Group’s PEAK Matrix® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

More News From Magnit Global

Back to Newsroom

Everest Group, Ltd. (EG) Q1 2026 Earnings Call Transcript

On April 30, 2026, Everest Group Ltd EG shares rose 3.7% today, reaching a current price of $356.76. This price is within a 52-week range of $302.44 to $368.29, highlighting the stock's recent upward momentum.

GF Value™ verdict: Current price is $356.76, which is 14.1% below the GF Value™ of $415.18.GF Score™ is 76/100, indicating an above-average rating based on several key financial metrics.Most notable signal: No insider transactions have been reported in the last three months. Is EG Overvalued or Undervalued? The current price of Everest Group Ltd EG is $356.76, which is 14.1% below the GF Value™ estimate of $415.18. This suggests that the stock is undervalued, presenting a potential opportunity for investors looking for stocks trading below their intrinsic value. The GF Valuation label indicates that EG is currently considered "Modestly Undervalued." This margin of safety could provide a buffer against market volatility, allowing investors to capitalize on a favorable pricing scenario.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Being undervalued does not guarantee future performance, and investors should consider the broader market conditions and company fundamentals before making any decisions.

How Does EG's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 7.3x 10.7x Forward P/E 6.8x - The current price-to-earnings (P/E) ratio for Everest Group Ltd EG is 7.3x, which is significantly below its 5-year median P/E of 10.7x, indicating that the stock is trading at a discount compared to its historical valuation. The forward P/E of 6.8x further emphasizes this undervaluation. This P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that EG is currently undervalued, presenting a favorable opportunity for investors.

What Does EG's GF Score™ Tell Us? Metric Rating GF Score™ 76 Financial Strength 5/10 Profitability 7/10 Growth 6/10 Valuation 10/10 Momentum 2/10 The GF Score™ of 76/100 indicates that Everest Group Ltd EG is rated above average in terms of long-term investment potential. The strongest area is the Valuation rank at 10/10, suggesting that the stock is significantly undervalued compared to its peers. However, the Momentum rank is notably low at 2/10, indicating potential weaknesses in the stock's price performance momentum. The scores highlight that while there are solid fundamentals, caution should be exercised regarding short-term price movements.

What Are Insiders Doing with EG Stock? In the last three months, there have been no reported insider transactions for Everest Group Ltd EG . This lack of insider activity may suggest that executives and board members are not currently buying or selling shares, which can indicate a neutral outlook on the company's near-term prospects. In environments where insiders are active, their transactions can provide valuable insights into their confidence in the company's future performance.

What This Means for Investors Based on the GF Value™ estimate, Everest Group Ltd EG is currently undervalued, presenting a potential opportunity for investors looking for stocks priced below their intrinsic value. However, as with any investment, it is important to consider a comprehensive analysis of the company's fundamentals and market conditions before making any decisions.

For the complete analysis, visit the Everest Group Ltd EG stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is EG's GF Score™?

EG's GF Score™ is 76/100, indicating that the stock is rated above average based on key financial metrics which have been shown to correlate with higher long-term returns.

Is EG overvalued or undervalued?

EG is considered undervalued, with a GF Value™ of $415.18 compared to the current price of $356.76, suggesting a potential investment opportunity.

What is EG's P/E ratio?

The current P/E (TTM) ratio for EG is 7.3x, which is significantly below its 5-year median P/E of 10.7x, indicating that the stock is currently trading at a discount compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

-

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (“Everest” or “the Company”) (NYSE: EG), a global underwriting leader providing world-class reinsurance and specialty insurance solutions, today announced the appointment of Lisa Davis as Head of North America, Wholesale & Specialty.

Ms. Davis will lead Everest’s North America Wholesale & Specialty business, overseeing underwriting strategy, distribution, and portfolio management across the region. She will report to Jason Keen, EVP and CEO of Global Wholesale & Specialty, and serve as a key member of his leadership team.

“Along with her extensive experience, Lisa brings a combination of underwriting discipline, operational leadership, and strong relationships that are critical in this environment,” said Jason Keen. “Her ability to build profitable specialty businesses, lead high-performing teams, and deepen broker relationships will be instrumental as we continue to strengthen our North America platform, deliver disciplined, profitable growth, and execute our long-term strategy.”

Ms. Davis brings more than 35 years of experience building and scaling specialty insurance businesses across wholesale markets, with deep expertise in underwriting leadership, portfolio management, and distribution strategy. Most recently, she led the build-out and expansion of Canopius’ U.S. business, delivering sustained profitable growth while significantly scaling the platform. Prior to that, she served as President and Chief Operating Officer for North America at Sompo America and held leadership roles at Zurich North America and St. Paul Companies.

About Everest

Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.

Everest common stock (NYSE: EG) is a component of the S&P 500 index.

Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.

More News From Everest Group, Ltd.

Back to Newsroom

-

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. announced that its Board of Directors declared a dividend of $2.00 per common share. This dividend will be payable on or before June 26, 2026 to all shareholders of record as of June 12, 2026.

About Everest
Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.

Everest common stock (NYSE: EG) is a component of the S&P 500 index.

Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.

More News From Everest Group, Ltd.

Back to Newsroom

Our top-performing stocks this quarter were Samsung Electronics, Shell and Lam Research. Our worst contributors were IQVIA, American Express and Heidelberg. We exited our investments in Everest Group and PayPal during the quarter.

-

NEW YORK--(BUSINESS WIRE)--American International Group, Inc. (NYSE: AIG) today announced it has entered into a definitive agreement to acquire Everest Compañía de Seguros Generales Colombia S.A. (“Everest Colombia”), Everest Group Ltd.’s (NYSE: EG) insurance subsidiary in Colombia. The acquisition of Everest Colombia strengthens AIG’s presence in the Latin America region and supports the company’s strategy to drive premium growth.

“This acquisition reinforces AIG’s commitment to our Latin America business and will enable us to accelerate our growth in one of the largest and fastest-growing insurance markets in the region,” said Jon Hancock, Executive Vice President and Chief Executive Officer, General Insurance, AIG. “With this acquisition, we are gaining a highly experienced team whose talent and deep understanding of the local market will strengthen our capabilities. Everest Colombia’s focus on corporate and upper-middle-market clients aligns with AIG’s commitment to expand our commercial insurance offerings to clients and brokers across the Latin America region.”

Upon completion of the transaction, subsidiaries of AIG will acquire 100 percent of the equity of Everest Colombia, including its licensed operations, employees and ongoing insurance business. AIG and Everest will work closely to ensure a seamless transition for clients, brokers and colleagues.

The transaction is expected to close in early 2027, subject to regulatory approvals and other customary closing conditions.

Evercore acted as financial advisor and Willkie Farr & Gallagher LLP and Brigard & Urrutia Abogados acted as legal counsel for AIG.

About AIG

American International Group, Inc. (NYSE: AIG) is a leading global insurance organization. AIG provides insurance solutions that help businesses and individuals in more than 200 countries and jurisdictions protect their assets and manage risks through AIG operations, licenses and authorizations as well as network partners. For additional information, visit www.aig.com. This website with additional information about AIG has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

AIG is the marketing name for the worldwide operations of American International Group, Inc. All products and services are written or provided by subsidiaries or affiliates of American International Group, Inc. Products or services may not be available in all countries and jurisdictions, and coverage is subject to underwriting requirements and actual policy language. Non-insurance products and services may be provided by independent third parties. Certain property casualty coverages may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds, and insureds are therefore not protected by such funds.

More News From American International Group, Inc.

Back to Newsroom

-

HAMILTON, Bermuda--(BUSINESS WIRE)--Everest Group, Ltd. (NYSE: RE) (“Everest”), a global underwriting leader, today announced the inaugural recipient of the Joseph V. Taranto Scholarship, an annual renewable award and part of the company’s broader commitment to expanding opportunity and developing the next generation of leaders.

Established by Everest and its Board of Directors in honor of former Chairman Joseph V. Taranto, the scholarship supports a college‑bound student who demonstrates academic excellence, financial need, and the qualities that have long defined both Everest and Mr. Taranto’s leadership: integrity, discipline, intellectual curiosity, and a commitment to service.

“Developing people and creating opportunity are fundamental to how we operate at Everest,” said Jim Williamson, Everest President and Chief Executive Officer. “This scholarship reflects our long-term commitment to investing in talent, both within our organization and in the communities we serve. It is one of many ways we’re helping build the next generation of leaders.”

The recipient was selected through a competitive process that assessed academic achievement, character, ambition, and alignment with Everest’s values.

The scholarship is part of Everest’s wider approach to “underwriting opportunity” through a combination of educational initiatives, community partnerships, and ongoing talent development programs designed to expand access and cultivate future industry leaders.

“I am deeply honored to have this scholarship carry my name,” said Joseph V. Taranto, former Chairman of Everest. “Throughout my career, I’ve believed that creating opportunities for others is the most meaningful legacy any leader can leave. Supporting young people with drive and ability is an investment that pays dividends in a broad and far-reaching way.”

The Joseph V. Taranto Scholarship complements Everest’s broader philanthropic and talent initiatives, including global giving programs, employee volunteerism, and internal development efforts that support continuous learning and career growth across the organization.

Through these efforts, Everest continues to advance its mission to “underwrite opportunity” for colleagues, customers, shareholders, and communities worldwide.

About Everest

Everest Group, Ltd. (Everest) is a global underwriting leader providing best-in-class property, casualty, and specialty reinsurance and insurance solutions that address customers’ most pressing challenges. Known for a 50-year track record of disciplined underwriting, capital and risk management, Everest, through its global operating affiliates, is committed to underwriting opportunity for colleagues, customers, shareholders, and communities worldwide.

Everest common stock (NYSE: EG) is a component of the S&P 500 index.

Additional information about Everest, our people, and our products can be found on our website at www.everestglobal.com.

More News From Everest Group, Ltd.

Back to Newsroom

ORLANDO, Fla.--(BUSINESS WIRE)--Everest Group has recognized Simform as an Aspirant in the Software Product Engineering Services PEAK Matrix® Assessment 2026 - Global and EMEA.

"Everest Group's recognition reinforces our investment in scalable engineering - our PexAI framework helps organizations harness AI across the SDLC, driving faster innovation and long-term value." - Prayaag Kasundra, CEO of Simform

Share The recognition highlights Simform’s capabilities in helping organizations design, build, and scale modern digital products through product engineering expertise, cloud platforms, AI-driven engineering practices, and reusable accelerators.

As enterprises modernize digital platforms and embed AI across products and development workflows, they are seeking partners that accelerate innovation while maintaining quality, governance, and cost discipline. Simform’s inclusion reflects its role as a strategic engineering partner for enterprises, digital-native businesses, and ISVs building scalable products and platforms.

Changing Expectations for Software Product Engineering Partners

Software product engineering is entering a new phase as AI becomes embedded across both products and the software development lifecycle (SDLC).

Organizations are modernizing legacy platforms, adopting microservices architectures, and applying AI-assisted development practices to accelerate releases and improve code quality.

These shifts are driving demand for partners that combine product engineering depth, reusable accelerators, scalable delivery models, and commercial accountability.

Simform’s inclusion in Everest Group’s Software Product Engineering Services PEAK Matrix® reflects the company’s growing momentum in helping organizations modernize platforms, strengthen engineering productivity, and integrate AI-enabled capabilities across complex software ecosystems.

AI-Powered Engineering Practices Across the SDLC

To support this shift, Simform has developed an AI-native product engineering model combining cross-functional engineering pods, reusable accelerators, and AI-assisted development practices.

At the center of this model is PexAI, Simform’s flagship product engineering excellence framework. PexAI combines reusable blueprints, engineering objective frameworks, and modernization accelerators that help teams standardize architecture, streamline workflows, and scale delivery.

The framework supports modernization initiatives such as microservices architecture, cloud re-platforming, and UI transformation while enabling platform engineering through modular architectures, API-first design, AI/ML capabilities, Agentic AI-features, and data integration.

Simform applies AI across the SDLC through PexAI-driven workflows that automate tech-stack specific task/workflow based code generation, pull request reviews, infrastructure-as-code pipelines, and shift-left testing and security. This enables AI-native engineers to combine human expertise with governed AI-assisted workflows that improve productivity while maintaining reliability and compliance.

Supporting this model are proprietary accelerators such as NeuVantage, which helps teams analyze and modernize legacy applications faster, CodeTools, which enables GitHub Copilot templates, workflow agents, and automation patterns, and ThoughtMesh, which supports enterprise-grade Agentic AI use cases, including corrective RAG and agentic architectures.

Together, these frameworks help teams reduce routine development work, improve code quality, and focus on product strategy and architecture.

Moving from Capacity-Based Engineering to Outcome-Led Delivery

As software platforms become central to enterprise growth, organizations increasingly expect partners to align delivery with measurable outcomes rather than purely capacity-based engagement models.

Simform’s co-engineering approach supports this shift by embedding engineering teams within client product organizations and aligning delivery around platform modernization milestones, engineering productivity improvements, and product innovation goals. Simform is also evolving toward outcome-based commercial models where pricing is increasingly aligned with clearly defined roadmap milestones and product outcomes. For example, modernization engagements may be tied to measurable platform improvements such as successful microservices migration, release cycle acceleration, or performance gains, while product engineering programs may link commercial models to feature delivery velocity, platform stability, or engineering productivity improvements. This approach helps clients align engineering investment with tangible progress while maintaining transparency and accountability across long-running product initiatives.

“We believe software product engineering should ultimately be measured by outcomes in some ways and how effectively teams can modernize platforms, accelerate innovation, and deliver lasting business value,” said Prayaag Kasundra, CEO of Simform.

“Our PexAI framework and co-engineering delivery model help organizations harness AI across the software development lifecycle while aligning engineering execution with meaningful product and business outcomes. This recognition from Everest Group reinforces the investments we have made in building scalable engineering capabilities that enable faster innovation and long-term value for our clients.”

Transforming and Scaling Platforms with Intelligent Automation

The role of AI in platform engineering is undergoing a fundamental shift - moving from isolated automation scripts to intelligent, agentic workflows that reshape how software products are designed, built, and scaled. It is transforming the end-to-end software delivery lifecycle - from predictive resource optimization and automated security remediation to self-healing observability and CI/CD pipelines. Companies that can operationalize these capabilities at scale are pulling ahead.

"Our PexAI Framework and AI-native practices help ISVs, Digital Native, and forward-looking enterprises to modernize platforms, ship faster, improve software quality, and reduce technical debt. We have come up with Enablement offerings to enable platform and development teams with AI-native practices too," said Hiren Dhaduk, CTO of Simform.

Building AI-Native GCC and CoE

Having built excellent AI-Native engineering practices, Simform is helping software engineering teams of ISVs and enterprises adopt these advanced and mature Agentic SDLC practices to accelerate roadmaps. Simform is also partnering with customers to launch AI-Native GCC in India to double down on the value realization of engineering investments.

In addition to enabling these teams with AI-native practices, Simform helps define the operating model, governance approach, and engineering workflows needed to make GCCs and CoEs productive from the start. By combining co-engineering expertise with frameworks such as PexAI and AI-assisted SDLC practices, Simform helps organizations scale engineering capacity, improve software quality, and turn GCCs into long-term innovation engines rather than delivery-only units.

To learn more about what this shift in software product engineering means for enterprise customers, read the blog published alongside this announcement.

About Simform

Simform is a digital engineering company specializing in Cloud, Data, AI, and Experience Engineering. With deep expertise across Microsoft Azure, Simform helps high-growth ISVs and tech-enabled enterprises build scalable, future-ready digital products and platforms through its co-engineering delivery model. With a rich heritage in Microsoft technologies, Simform is recognized as a Solution Partner for Digital and App Innovation, Data & AI, Infrastructure and Security. Our team boasts 340+ Azure-certified infrastructure, cloud-native applications, data, AI and security engineers. With more than 15 years of experience, Simform delivers solutions for high-tech, fintech, healthcare & life sciences, supply chain & logistics, retail & ecommerce, and professional services industries.

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases

Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere’s pipeline

Company to host conference call June 2, 2026 at 8:30 a.m. ET

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.

Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases.

Share “Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”

“This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney diseases, including primary membranous nephropathy (PMN), with planned evaluation in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and potentially additional indications. BTK is a key mediator of B-cell receptor signaling and plays an important role in B-cell activation, maturation, proliferation, and differentiation into antibody-producing cells.

In immune-mediated kidney diseases, B-cell activation and autoantibody production are believed to contribute directly to kidney injury. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. Civorebrutinib has been generally well tolerated throughout the development program to date.

As innovation in rare kidney diseases continues to accelerate, patients still face significant unmet need and limited treatment options across many serious conditions. Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. Civorebrutinib may also broaden future treatment approaches in FSGS, where both nephroprotective and targeted immune control approaches may play important roles.

Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million in exchange for granting Travere exclusive development and commercialization rights for civorebrutinib in all markets outside of China and certain countries in East and Southeast Asia. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

Conference Call Information

Travere Therapeutics will host a conference call and webcast today, Tuesday, June 2, 2026, at 8:30 a.m. ET. To participate in the conference call, dial +1 (833) 461-5787 (U.S.) or +1 (585) 542-9983 (International), conference ID 574 733 925 shortly before 8:30 a.m. ET. The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

About Civorebrutinib

Civorebrutinib (also known as EVER001) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell autoimmune diseases.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

Forward Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements regarding the Company's beliefs about the future potential of its pipeline and portfolio; statements regarding the Company's capabilities, competitive positioning, and strategic plans; statements and expectations regarding the potential of civorebrutinib to serve as a pipeline-in-a-product and to potentially become a best-in-class therapy across multiple immune-mediated kidney diseases, and its potential to provide differentiated efficacy, safety and convenience for the indications described herein; statements and expectations regarding the expected broad mechanistic applicability across diseases; statements and expectations regarding future treatment approaches and paradigms; statements and expectations regarding the clinical studies and data described herein; statements and expectations regarding potential future payments (including upfront, milestone and royalty payments) and, as applicable, the potential achievement and timing thereof; statements and expectations regarding the activities of the Company’s partners and collaborators; and statements related to the estimated sizes of patient populations. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the license agreement with Everest, including the ability of the parties to obtain required regulatory approvals and satisfy other applicable conditions, and the ability of the Company to successfully advance the product through clinical trials toward potential future regulatory approval. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. Specifically, the Company faces risks associated with the commercial launch of FILSPARI in FSGS and the ongoing commercialization in IgAN, the timing and potential outcome of its and its partners’ clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the current administration, including but not limited to risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, including potential ANDA filings or patent challenges, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

More News From Travere Therapeutics, Inc.

Everest Group benefits from underwriting discipline, rising investment income and global expansion while returning significant capital to shareholders.